Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 1, 2007, Pages 275-282

  Brugue, Esteve ^a   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Atypical antipsychotics; Bipolar disorder; Depression; Dopamine

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; LITHIUM; METHAMPHETAMINE; MONOAMINE; MOOD STABILIZER; NOMIFENSINE; OLANZAPINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2 RECEPTOR; TYROSINE; ZIPRASIDONE;

AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG USE; GUILLAIN BARRE SYNDROME; HUMAN; INSOMNIA; MONOTHERAPY; MOOD; MOTOR DYSFUNCTION; PSYCHOSIS; RECEPTOR OCCUPANCY; SEDATION; SEIZURE; SEROTONINERGIC SYSTEM; SIDE EFFECT; SUICIDE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; BIPOLAR DISORDER; CLINICAL TRIALS; DEPRESSION; HUMANS;

EID: 33845603948     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.06.014     Document Type: Article

References (82)

1. Altshuler L.L., Gitlin M.J., Mintz J., Leight K.L., and Frye M.A. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 63 (2002) 807-811
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65 (2004) 267-272
3. Amin F., Davidson M., Kahn R.S., Schmeidler J., Stern R., Knott P.J., et al. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull 21 (1995) 53-66
4. Asberg M., Bertilsson L., and Martensson B. CSF monoamine metabolites, depression, and suicide. Adv Biochem Psychopharmacol 39 (1984) 87-97
5. Bunney W.E., and Davis J.M. Norepinephrine in depressive reactions: a review. Arch Gen Psychiatry 13 (1965) 483-494
6. Calabrese J.R., Rapport D.J., and Shelton M.D. Pursuit of the ideal mood stabilizer: time to give up and move to combination trials. In: Maj M., Akiskal H.S., Lopez-Ibor J.J., and Sartorius N. (Eds). Bipolar disord (2002), John Wiley and Son Ltd. 222-224
7. Calabrese J.R., Bowden C.L., Sachs G., Yatham L.N., Behnke K., Mehtonen O.P., et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64 (2003) 1013-1024
8. Calabrese J.R., Vieta E., El-Mallakh R., Findling R.L., Youngstrom E.A., Elhaj O., et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 56 (2004) 957-963 (Dec)
9. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weissler R.H., et al. A randomised double-blind placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162 (2005) 1351-1360
10. Chou J., Czobor P., Tuma I., Charles O., Bebe R., Cooper T.B., et al. Pretreatment plasma HVA and haloperidol response in acute mania. J Affect Disord 59 (2000) 55-59
11. Colom F., Vieta E., Martinez-Aran A., Reinares M., Goikolea J.M., Benabarre A., et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 60 (2003) 402-407
12. Koslow S.H., Maas J.W., Bowden C.L., Davis J.M., Hanin I., and Javaid J. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. Arch Gen Psychiatry 40 (1983) 999-1010
13. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M., et al. Ziprasidone 80 mg/d and 160 mg/d in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo controlled trial. Neuropsychopharmacology 20 (1999) 491-505
14. D'Aquila P.S., Collu M., Gessa G.L., and Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 405 (2000) 365-373
15. 2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 35 (1994) 128-132
16. Duman R.S. Synaptic plasticity and mood disorders. Mol Psychiatry 7 (2002) 29-34
17. 2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 126 (1996) 91-94
18. Erfurth A., Michael N., Stadtland C., and Arolt V. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology 45 (2002) 33-36
19. Frye M.A., Gitlin M.J., and Altshuler L.L. Unmet needs in bipolar depression. Depress Anxiety 19 (2004) 199-208
20. Goldberg J.F., Burdick K.E., and Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 161 (2004) 564-566
21. Golden R.N., Rudorfer M.V., Sherer M.A., Linnoila M., and Potter W.Z. Bupropion in depression: biochemical effects and clinical response. Arch Gen Psychiatry 45 (1988) 139-142
22. Gottberg E., Montreuil B., and Reader T.A. Acute effects of lithium on dopaminergic responses: iontophoretic studies in the rat visual cortex. Synapse 2 (1988) 442-449
23. Hubble J.P. Long-term studies of dopamine agonists. Neurology 58 (2002) 42-50
24. Ichikawa J., Li Z., Dai J., and Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 29 (2002) 349-357 (Nov)
25. Jones I., and Craddock N. Candidate gene studies of bipolar disorder. Ann Med 33 (2001) 248-256
26. Judd L.L., and Akiskal H.S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 73 (2003) 123-131
27. Kalivas P.W., Churcill L., and Klitenick M.A. The circuitry mediating the translation of motivational stimuli into adaptive motor responses. Limbic motor circuits and neuropsychiatry (1993), CRC Press 237-287
28. 2 receptro occupancy. Arch Gen Psychiatry 57 (2000) 553-559
29. 2 receptor agonist antipsychotic. Expert Opin Invest Drugs 12 (2003) 655-662
30. Keck Jr. P.E., Calabrese J.R., McQuade R.D., Carson W.H., Carlson B.X., Rollin L.M., et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67 (2006) 626-637
31. Ketter T.A., Tohen M.F., and Vieta E. Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. Bipolar Disord 6 (2004) 27
32. 123I]IBZM SPECT. Psychiatry Res 90 (1999) 91-101
33. Koch S., Perry K.W., and Bymaster F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 46 (2004) 232-242
34. Lambert G., Johansson M., Agren H., and Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: Evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 57 (2000) 787-793
35. Lane H.Y., Lin Y.C., and Chang W.H. Mania induced by risperidone: dose related?. J Clin Psychiatry 59 (1998) 85-86 (Letter)
36. Lecrubier Y., Boyer P., Turjanski S., and Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord 43 (1997) 95-103
37. Lindley S.E., Bengoechea T.G., Schatzberg A.F., and Wong D.L. Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. Neuropsychopharmacology 21 (1999) 399-407
38. Lyons D.M., Lopez J.M., Yang C., and Schatzberg A.F. Stress-level cortisol treatment impairs inhibitory control of behaviour in monkeys. J Neurosci 20 (2000) 7816-7821
39. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray A., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53 (2003) 707-742
40. Mazure C.M., and Bowers M.B. Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. J Affect Disord 48 (1998) 83-86
41. McTavish S.F., McPherson M.H., Harmer C.J., Clark L., Sharp T., Goodwin G.M., et al. Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry 179 (2001) 356-360
42. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial. Arch Gen Psychiatry 60 (2003) 82-91
43. Mitchell P.B., and Malhi G.S. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord 6 (2004) 530-539
44. Musselman D.L., DeBattista C., Nathan K.I., Kilts C.D., Schatzberg A.F., and Nemeroff C.B. Biology of mood disorders. In: Schatzberg A.F., and Nemeroff C.B. (Eds). Psychopharmacology (1998), American Psychiatric Press 549-588
45. Nierenberg A.A., Dougherty D., and Rosenbaum J.F. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 59 (1998) 60-64
46. Nordin C. Relationships between clinical symptoms and monoamine metabolite concentrations in biochemically defined subgroups of depressed patients. Acta Psychiatr Scand 78 (1988) 720-729
47. Nurnberger Jr. J.J., Gershon E.S., Simmons S., Ebert M., Kessler L.R., and Dibble E.D. Behavioural, biochemical and neurochemical responses to amphetamine in normal twins and 'well-state' bipolar patients. Psychoneuroendocrinology 7 (1982) 163-176
48. Ordway G.A., Klimek V., and Mann J.J. Neurocircuitry of mood disorders. In: Davis K.L., Charney D., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: the fifth generation of progress (2002), Lippincott Williams and Wilkins 1051-1064
49. Parker G., Hadzi-Pavlovic D., Brodaty H., Boyce P., Mitchell P., Wilhelm K., et al. Psychomotor disturbance in depression: defining the constructs. J Affect Disord 27 (1993) 255-265
50. 3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 21 (1998) 141-151
51. Placidi G.P., Oquendo M.A., Malone K.M., Huang Y.Y., Ellis S.P., and Mann J.J. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry 50 (2001) 783-791
52. Post RM. (2004): Antidepressant effects of the atypical antipsychotic quetiapine. Post RM as Ed-in-chief of Bipolar Network News 10:4-7. Permission for publication granted on 11.05.2006.
53. Qing H., Xu H., Wei Z., Gibson K., and Li X.M. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 17 (2003) 1563-1570
54. Randrup A., Munkvad I., and Fog R. Mania, depression and brain dopamine. Current developments in psychopharmacology vol. 2 (1975), Spectrum Press, New York 206-248
55. Raskin A., Schulterbrandt J.G., Reatig N., and McKeon J.J. Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry 23 (1970) 64-73
56. Reddy P.L., Khanna S., Subhash M.N., Channabasavanna S.M., and Rao B.S. CSF amine metabolites in depression. Biol Psychiatry 31 (1992) 112-118
57. Renard C.E., Fiocco A.J., Clenet F., Hascoet M., and Bourin M. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?. Psychopharmacology 159 (2001) 42-50
58. Sachs G.S., Lafer B., Stoll A.L., Banov M., Thibault A.B., Tohen M., et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55 (1994) 391-393
59. Sachs G.S., Printz D.J., Kahn D.A., Carpenter D., and Docherty J.P. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 1 (2000) 1-104
60. Schatzberg A.F., Rothschild A.J., Langlais P.J., Bird E.D., and Cole J.O. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19 (1985) 57-64
61. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122 (1965) 509-522
62. Schmidt A.W., Lebel L.A., and Johnson C.G. The novel antipsychotic ziprasidone has a unique human receptor binding profile compared to other agents. Soc Neurosci Abstr 24 (1998) 2177
63. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47 (2002) 27-38
64. Severino G., Congiu D., Serreli C., De Lisa R., Chillotti C., Del Zompo M., et al. A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. Am J Med Genet 5 (2005) 37-38
65. 2 binding in depression. Psychol Med 27 (1997) 1247-1256
66. Silverstone T. Dopamine in manic depressive illness: a pharmacological synthesis. J Affect Disord 8 (1985) 225-231
67. Stahl S.M. Depression and bipolar disorders. Essential psychopharmacology of depression and bipolar disorder (2000), Cambridge University Press 55-58
68. Tohen M.F., Marneros A., Bowden C.L., et al. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month trial. Bipolar Disord 4 (2002) 135
69. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60 (2003) 1079-1088
70. Tohen M.F., Bowden C.L., and Calabrese J.R. Olanzapine versus placebo for relapse prevention in bipolar disorder. 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, USA, 17-22 May 2003 (2003)
71. Tohen M., Chengappa K.N., Suppes T., Baker R.W., Zarate C.A., Bowden C.L., et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry 184 (2004) 337-345
72. Vieta E. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 16 (2003) 23-27
73. Vieta E. Case for caution, case for action. Bipolar Disord 5 (2003) 434-435
74. Vieta E., and Colom F. Psychological interventions in bipolar disorder: from wishful thinking to an evidence-based approach. Acta Psychiatr Scand 422 (2004) 34-38
75. Vieta E., and Goikolea J.M. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 7 (2005) 21-33
76. Vieta E., Nolen W., Grunze H., Licht R., and Goodwin G. A European perspective on the Canadian guideline for bipolar disorder. Bipolar Disord 7 (2005) 73-76
77. Whiskey E., and Taylor D. Pramipexole in unipolar and bipolar depression. Psychiatri Bull 28 (2004) 438-440
78. Willner P. Dopamine and depression: a review of recent evidence, part. Brain Res 287 (1983) 225-236
79. Xu H., Qing H., Lu W., Keegan D., Richardson J.S., Chlan-Fourney J., et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 321 (2002) 65-68
80. Yatham L.N., Goldstein J.M., Vieta E., Bowden C.L., Grunze H., Post R.M., et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 66 (2005) 40-48
81. Zarate Jr. C.A., Payne J.L., Singh J., Quiroz J.A., Luckenbaugh D.A., Denicoff K.D., et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 56 (2004) 54-60
82. Zornberg G.L., and Pope Jr. H.G. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 13 (1993) 397-408